Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PTH assay: new and future].

S Nakanishi1, M Fukagawa

  • 1Division of Dialysis and Metabolism, Kobe University School of Medicine.

Clinical Calcium
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

Adynamic bone disease is common in dialysis patients. Current intact parathyroid hormone (PTH) assays may overestimate PTH activity, suggesting whole PTH assays are better for assessing bone health in uremia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of postoperative biomechanical function between anatomic double-bundle and single-bundle ACL reconstructions using calcium phosphate-hybridized tendon grafts in goats.

Orthopaedics & traumatology, surgery & research : OTSR·2017
Same author

Two cases of nephrotic syndrome (NS)-induced acute kidney injury (AKI) associated with renal hypouricemia.

Clinical nephrology·2011
Same author

Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride.

Clinical nephrology·2010
Same author

Contrast-induced ultrasonography with Levovist in a case of exercise-induced acute kidney injury without rhabdomyolysis.

Clinical nephrology·2010
Same author

FGF23: a key player in mineral and bone disorder in CKD.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2009
Same author

The making of a bone in blood vessels: from the soft shell to the hard bone.

Kidney international·2007

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Context:

  • Chronic dialysis patients frequently develop bone disease, with adynamic bone disease posing a significant challenge.
  • Elevated parathyroid hormone (PTH) levels are implicated in maintaining bone turnover in uremia.
  • Current therapeutic targets for PTH in uremic patients are based on intact PTH (iPTH) assays, typically set between 150-200 pg/ml.

Purpose:

  • To evaluate the limitations of conventional intact PTH assays in uremic patients.
  • To explore the potential of whole PTH assays for more accurate assessment of PTH activity.
  • To advocate for revised PTH target ranges considering assay specificities.

Summary:

  • Conventional intact PTH assays may inaccurately reflect circulating PTH activity due to PTH molecule instability and the detection of inactive fragments (7-84 PTH) alongside the active form (1-84 PTH).

Related Experiment Videos

  • The 7-84 PTH fragment is suggested to inhibit the action of 1-84 PTH, potentially leading to an overestimation of PTH's biological activity in uremic patients.
  • Whole PTH assays, which specifically measure 1-84 PTH, may offer a more precise evaluation of PTH activity in this population.

    • Impact:

    • Highlights the need for improved diagnostic methods for bone disease in chronic kidney disease patients.
    • Suggests that current PTH monitoring strategies may require revision.
    • Emphasizes the importance of considering PTH fragment analysis for optimizing treatment and patient outcomes in uremia.